SIA
VRTX icon

SGL Investment Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

SGL Investment Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546K Buy
+1,043
New +$462K 0.19% 93
2025
Q2 		– Sell
-1,323
Closed -$568K – 126
2025
Q1 		$568K Sell
1,323
-10
-0.8% -$4.66K 0.29% 66
2024
Q4 		$604K Buy
1,333
+12
+0.9% +$5.56K 0.3% 65
2024
Q3 		$639K Buy
+1,321
New +$635K 0.33% 64

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

SGL Investment Advisors's VRTX Position: Q2 2026 in Review

SGL Investment Advisors opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 1,043 shares worth $546K. The stake represents 0.19% of the portfolio and ranks #93 among its holdings. This is a return to the name: SGL Investment Advisors previously reported a position in VRTX as recently as Q1 2025.

SGL Investment Advisors first reported a position in VRTX in Q3 2024 and has held it in 4 quarters since. The position peaked at $639K in Q3 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • SGL Investment Advisors held 1,043 shares of Vertex Pharmaceuticals worth $546K as of Q2 2026.
  • Vertex Pharmaceuticals was a new SGL Investment Advisors position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.19% of SGL Investment Advisors's portfolio in Q2 2026, its #93 holding.
  • SGL Investment Advisors first reported a position in Vertex Pharmaceuticals in Q3 2024 and has held it in 4 quarters since.
  • SGL Investment Advisors's Vertex Pharmaceuticals position peaked at $639K in Q3 2024.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on SGL Investment Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.